Enlivex Therapeutics (NASDAQ:ENLV) has received a downgrade from analysts at D Boral Capital, shifting its rating from a “strong-buy” to a “hold.” This decision was communicated to investors on Monday, marking a significant change in the outlook for the clinical-stage immunotherapy company.
Other analysts have provided varying assessments of Enlivex’s stock. HC Wainwright reaffirmed a “buy” rating with a target price of $7.00 in a research note released on September 2, 2023. Conversely, Weiss Ratings assigned a “sell (e+)” rating on November 11, 2023, while Wall Street Zen changed its rating to “sell” on August 30, 2023. Currently, the stock has received one “buy” rating, two “hold” ratings, and one “sell” rating, resulting in an average rating of “hold” and a target price of $10.00, according to data from MarketBeat.com.
Investor Activity and Institutional Insights
Recent trading activity indicates a growing interest in Enlivex among institutional investors. Notable transactions include Susquehanna International Group LLP acquiring a new stake valued at approximately $57,000 in the third quarter. Citizens Financial Group Inc. (RI) also entered a new position worth around $241,000. Additionally, Jane Street Group LLC significantly increased its stake by 527.4% in the first quarter, now holding 80,759 shares, valued at approximately $78,000 after purchasing an additional 67,886 shares in the last quarter. Overall, institutional investors and hedge funds collectively own 1.02% of Enlivex’s stock.
Company Overview and Product Pipeline
Enlivex Therapeutics Ltd., based in Israel, specializes in macrophage reprogramming immunotherapy. The company’s lead product, Allocetra, is currently undergoing a phase II clinical trial aimed at treating organ dysfunction caused by sepsis. Furthermore, Allocetra is being developed for moderate and end-stage knee osteoarthritis, with trials in phase I/II.
As investors continue to monitor Enlivex’s performance and the evolving market landscape, the company’s next steps in clinical development and regulatory advancements will be pivotal in shaping its future trajectory.
